AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of $1.23 billion. The enterprise value is $1.33 billion.

Market Cap	1.23B
Enterprise Value	1.33B

Important Dates

The last earnings date was Tuesday, November 4, 2025, after market close.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

AnaptysBio has 27.69 million shares outstanding. The number of shares has increased by 7.36% in one year.

Current Share Class	27.69M
Shares Outstanding	27.69M
Shares Change (YoY)	+7.36%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	2.85%
Owned by Institutions (%)	70.65%
Float	14.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.70
Forward PS	6.90
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.68

Current Ratio	8.68
Quick Ratio	8.52
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.37

Financial Efficiency

Return on equity (ROE) is -308.02% and return on invested capital (ROIC) is -4.66%.

Return on Equity (ROE)	-308.02%
Return on Assets (ROA)	-4.23%
Return on Invested Capital (ROIC)	-4.66%
Return on Capital Employed (ROCE)	-9.10%
Revenue Per Employee	$1.25M
Profits Per Employee	-$622,279
Employee Count	136
Asset Turnover	0.40
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid $77,000 in taxes.

Income Tax	77,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +84.43% in the last 52 weeks. The beta is 0.29, so AnaptysBio's price volatility has been lower than the market average.

Beta (5Y)	0.29
52-Week Price Change	+84.43%
50-Day Moving Average	35.35
200-Day Moving Average	24.60
Relative Strength Index (RSI)	71.45
Average Volume (20 Days)	751,826

Short Selling Information

The latest short interest is 5.93 million, so 21.42% of the outstanding shares have been sold short.

Short Interest	5.93M
Short Previous Month	6.85M
Short % of Shares Out	21.42%
Short % of Float	41.17%
Short Ratio (days to cover)	11.05

Income Statement

In the last 12 months, AnaptysBio had revenue of $169.47 million and -$84.63 million in losses. Loss per share was -$2.88.

Revenue	169.47M
Gross Profit	16.47M
Operating Income	-28.68M
Pretax Income	-84.55M
Net Income	-84.63M
EBITDA	-28.10M
EBIT	-28.68M
Loss Per Share	-$2.88

Full Income Statement

Balance Sheet

The company has $248.96 million in cash and $346.45 million in debt, giving a net cash position of -$97.49 million or -$3.52 per share.

Cash & Cash Equivalents	248.96M
Total Debt	346.45M
Net Cash	-97.49M
Net Cash Per Share	-$3.52
Equity (Book Value)	-29.42M
Book Value Per Share	-1.07
Working Capital	292.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$144.97 million and capital expenditures -$349,000, giving a free cash flow of -$145.32 million.

Operating Cash Flow	-144.97M
Capital Expenditures	-349,000
Free Cash Flow	-145.32M
FCF Per Share	-$5.25

Full Cash Flow Statement

Margins

Gross margin is 9.72%, with operating and profit margins of -16.92% and -49.94%.

Gross Margin	9.72%
Operating Margin	-16.92%
Pretax Margin	-49.89%
Profit Margin	-49.94%
EBITDA Margin	-16.58%
EBIT Margin	-16.92%
FCF Margin	n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.36%
Shareholder Yield	-7.36%
Earnings Yield	-6.89%
FCF Yield	-11.83%

Analyst Forecast

The average price target for AnaptysBio is $63.80, which is 43.66% higher than the current price. The consensus rating is "Buy".

Price Target	$63.80
Price Target Difference	43.66%
Analyst Consensus	Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	34.63%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of -1.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.06
Piotroski F-Score	3